跳至主要内容
临床试验/NCT06275256
NCT06275256尚未招募3 期

Outcomes of Minimally Invasive Surgical Treatments (MIST) for Benign Prostatic Hyperplasia (BPH): A Single-Institution Prospective Study

University of Manitoba2 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2024年3月最近更新:
适应症

试验速览

阶段
3 期
状态
尚未招募
入组人数
20
试验地点
2
主要终点
Symptom Scores

研究概览

简要总结

The investigators wish to perform a prospective study at the Men's Health Clinic in Winnipeg, Manitoba to accomplish two goals: 1) Prospectively describe 1 year outcomes for MIST therapies performed at the clinic 2) perform a head to head comparison of Rezum water vapor therapy vs the iTind device in respect to symptom score improvement, uroflow parameters and side effect profile.

详细描述

This prospective study is to be conducted at the Men's Health Clinic in Winnipeg, Manitoba. All eligible patients who are to undergo Rezum or iTind procedure for BPH/LUTS between March 2024 and March 2025 are to be included in the study. Patient meeting inclusion criteria and exclusion criteria will be recruited to participate in this study.

Inclusion criteria: patients > 18 years of age, undergoing Rezum or iTind treatment Exclusion criteria: ASA III or higher, active UTI within past week, age < 18 years of age, no informed consent Follow-up/data measurements will occur pre-procedure, immediately post procedure, 1 week, 6 weeks, and 3 months following procedure. At time of consultation pre-procedure, baseline symptom scores, uroflow parameters will be obtained. VAS pain score is to be obtained during procedure, immediately post procedure, and at time of catheter or device removal 1 week post procedure. Uroflow parameters and symptoms scores will be again measured at 6 weeks and 3 months.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • patients > 18 years of age undergoing Rezum or iTind treatment

排除标准

  • ASA 3 or higher, active UTI within past week, age < 18 years of age, no informed consent

结局指标

主要结局

Symptom Scores

时间窗: 1, 3, 6 months post-procedure

Using the IPSS (International Prostate Symptom Score) questionnaires to measure improvement in symptom scores

Uroflow

时间窗: 1, 3, 6 months post-procedure

Measuring uroflow parameters such as Qmax pre and post procedure

次要结局

  • Pain Scale(1, 3, 6 months post-procedure)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Premal Patel, MD

Assistant Professor, Department of Surgery. Director, Undergraduate Urologic Medical Education

University of Manitoba

研究点 (2)

Loading locations...

相似试验